Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Accelerated bone formation by biphasic calcium phosphate with a novel sub-micron surface topography
Abstract: Osteoinductive calcium phosphate (CaP) bone grafts have equivalent performance to autografts in repairing critical-size bone defects. The osteoinductive potential of CaP is linked to the size of the surface topographical features. In the present study, two novel biphasic calcium phosphate (BCP) bone grafts were synthesised with either sub-micron- (BCP<μm) or micron-scale (BCPμm) needle-shaped surface topography and compared to dimensionally similar tricalcium phosphate (TCP) with grain-shaped surface structures (TCP<μm and TCPμm). To clarify the possible function of the surface morphology (needle-like vs. grain-like) in initiating bone formation, the four CaP test materials were physicochemically characterised and implanted for 12 weeks in the dorsal muscle of beagles. The sub-micron needle-shaped topography of BCP<μm triggered earlier bone formation (3-6 weeks) as compared to the grain-shaped surface topography of TCP<μm, which formed bone at 6-9 weeks. After 12 weeks, the amount of induced bone formation in both materials was equivalent, based on histomorphometry. The micron-sized needle-shaped surface topography of BCPμm led to limited formation of new bone tissue, whereas its counterpart, TCPμm with grain-shaped surface topography, failed to trigger de novo bone formation. The relative strength of the parameters affecting CaP-driven bone induction was as follows: surface feature size > surface feature morphology > substrate chemistry. BCP materials with needleshaped sub-micron surface topography gave rise to accelerated bone formation and slower rate of resorption than a comparable TCP. These characteristics may be translated to improve bone healing in orthotopic defects.
Abstract faithfully reproduced from the source: Eur Cell Mater. 2019 Jan 28;37:60-73.
Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. MagnetOs is not cleared by FDA as an osteoinductive bone graft. Please refer to the instructions for use for a full list of indications, contraindications, warnings and precautions.